Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
<p>Abstract</p> <p>Background</p> <p>We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes.</p&g...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-12-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/689 |
id |
doaj-f54934c866584d2aab50c34a88778906 |
---|---|
record_format |
Article |
spelling |
doaj-f54934c866584d2aab50c34a887789062020-11-25T00:05:19ZengBMCBMC Cancer1471-24072010-12-0110168910.1186/1471-2407-10-689Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal OriginMaeder UweMorris David LDoerfer JoergStojadinovic AlexanderEsquivel JesusChua Terence CPelz Joerg OWGermer Christoph-ThomasKerscher Alexander G<p>Abstract</p> <p>Background</p> <p>We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes.</p> <p>Methods</p> <p>One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test.</p> <p>Results</p> <p>Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001].</p> <p>Conclusion</p> <p>A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.</p> http://www.biomedcentral.com/1471-2407/10/689 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maeder Uwe Morris David L Doerfer Joerg Stojadinovic Alexander Esquivel Jesus Chua Terence C Pelz Joerg OW Germer Christoph-Thomas Kerscher Alexander G |
spellingShingle |
Maeder Uwe Morris David L Doerfer Joerg Stojadinovic Alexander Esquivel Jesus Chua Terence C Pelz Joerg OW Germer Christoph-Thomas Kerscher Alexander G Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin BMC Cancer |
author_facet |
Maeder Uwe Morris David L Doerfer Joerg Stojadinovic Alexander Esquivel Jesus Chua Terence C Pelz Joerg OW Germer Christoph-Thomas Kerscher Alexander G |
author_sort |
Maeder Uwe |
title |
Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin |
title_short |
Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin |
title_full |
Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin |
title_fullStr |
Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin |
title_full_unstemmed |
Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin |
title_sort |
evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (psdss) for peritoneal carcinomatosis of colorectal origin |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2010-12-01 |
description |
<p>Abstract</p> <p>Background</p> <p>We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes.</p> <p>Methods</p> <p>One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test.</p> <p>Results</p> <p>Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001].</p> <p>Conclusion</p> <p>A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.</p> |
url |
http://www.biomedcentral.com/1471-2407/10/689 |
work_keys_str_mv |
AT maederuwe evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT morrisdavidl evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT doerferjoerg evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT stojadinovicalexander evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT esquiveljesus evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT chuaterencec evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT pelzjoergow evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT germerchristophthomas evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin AT kerscheralexanderg evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin |
_version_ |
1725425745832968192 |